Madrigal Stock Rises as Q1 Results Beat Estimates and Rezdiffra Sales Fuel Strong MASH Market Growth
Madrigal Stock Rises as Q1 Results Beat Estimates and Rezdiffra Sales Fuel Strong MASH Market Growth
Madrigal Pharmaceuticals delivered a stronger-than-expected first-quarter performance, helped by rapid sales growth for Rezdiffra, its treatment for metabolic dysfunction-associated steatohepatitis, or MASH. The company reported first-quarter 2026 net revenue of $311.3 million, up 127% from the same period last year. More than 42,250 patients were on Rezdiffra as of March 31, 2026.
Rezdiffra Drives Madrigalâs Revenue Growth
The quarter showed that Rezdiffra remains the main growth engine for Madrigal. Because Rezdiffra is the companyâs key commercial product, its strong demand directly lifted the top line. Patient use increased sharply from the prior year, supported by wider physician adoption and stronger awareness of MASH as a serious liver disease.
Madrigal said Rezdiffra has reached âblockbusterâ status on a trailing-12-month net sales basis. The company also noted that the diagnosed market has expanded to about 460,000 patients over two years, giving Madrigal a larger opportunity to grow sales in 2026 and beyond.
Q1 Financial Performance Beats Expectations
Madrigal reported a first-quarter net loss of $94.4 million, or $3.25 per share. Although the company remained unprofitable, the loss was narrower than analyst expectations. Revenue also topped market estimates, helped by Rezdiffraâs strong commercial momentum.
Operating expenses rose to $404.1 million, compared with $216.6 million a year earlier. The increase came from higher commercial spending, research investment, and one-time business development costs tied to pipeline expansion. Madrigal ended the quarter with $817.9 million in cash, restricted cash, and marketable securities.
Pipeline Expansion Strengthens Long-Term Strategy
Beyond Rezdiffra, Madrigal is expanding its MASH pipeline. The company signed a global licensing agreement for a clinical-stage siRNA asset targeting PNPLA3, a genetic driver linked to MASH progression. This could help Madrigal develop more targeted treatments for patients at higher risk of advanced liver fibrosis.
The company is also preparing to advance MGL-2086, an oral GLP-1 candidate, into a Phase 1 trial in the second quarter of 2026. In addition, a drug-drug interaction study involving ervogastat and resmetirom is planned for the fourth quarter of 2026.
Why Investors Reacted Positively
Investor optimism appears to be tied to three main points: revenue growth, patient adoption, and the size of the MASH market. Even though Madrigal still posted a loss, the company showed that Rezdiffra is gaining traction in a market with high unmet medical need.
MASH can progress to serious liver complications, including cirrhosis and liver failure. Madrigal describes Rezdiffra as a once-daily oral, liver-directed therapy for MASH with moderate to advanced fibrosis. The drug was the first medication approved by both the FDA and European Commission for this patient group.
Outlook
Madrigalâs first-quarter report suggests that Rezdiffra remains on a strong growth path. The company is spending heavily to support commercial expansion, research, and new pipeline assets, which may keep pressure on earnings in the near term. However, rising patient numbers, strong sales growth, and a broader MASH strategy give investors reasons to watch Madrigal closely through the rest of 2026.
Overall, the quarter marked an important step for Madrigal as it works to turn Rezdiffraâs early success into long-term leadership in the MASH treatment market.
#MadrigalPharmaceuticals #MDGL #Rezdiffra #MASH #SlimScan #GrowthStocks #CANSLIM